clinical trial · NCT06285643
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
AskBio Inc·phase2·recruiting·n = 127
Parkinson DiseaseAAV2-GDNF gene therapycontrol surgery
brief summary
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
started
Jun 11, 2024
primary completion
Aug 31, 2028
completion
Aug 31, 2028
last updated
Dec 8, 2025
official title
A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol